Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04516694 · ClinicalTrials.gov registry record · NA

Promoting Adolescent Investment In Diabetes Care

A NA study of Type 1 Diabetes, sponsored by Harvard Pilgrim Health Care.

Completed
Registry status
NA
Development phase
39
Enrollment target
1
Study location

NCT04516694 is a NA study of Type 1 Diabetes that has completed, run by Harvard Pilgrim Health Care. The registered enrollment target is 39 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04516694, a NA study of Type 1 Diabetes, has completed, sponsored by Harvard Pilgrim Health Care.

COMPLETED
Registry status
NA
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

Two financial incentive strategies targeting adolescents with type 1 diabetes will be compared to usual care for motivating adolescents to engage in improved self-care to manage their diabetes.

Conditions Studied

Interventions

  • BEHAVIORAL Financial incentive (gain)
  • BEHAVIORAL Financial incentive (loss)

Study Locations (1)

Washington

  • Seattle Children's Research Institute - Seattle

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2020-09-10
Est. Completion 2022-01-08
Phase NA

Sponsor

Harvard Pilgrim Health Care

28 total trials

What the Registry Record Tells You About NCT04516694

The ClinicalTrials.gov registry entry for NCT04516694 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is Harvard Pilgrim Health Care, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Financial incentive (gain) is the first listed.

NCT04516694 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT04516694 about?

NCT04516694 is a clinical study titled "Promoting Adolescent Investment In Diabetes Care". Two financial incentive strategies targeting adolescents with type 1 diabetes will be compared to usual care for motivating adolescents to engage in improved self-care to manage their diabetes.

What is the current status of trial NCT04516694?

This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2020-09-10. Estimated completion is 2022-01-08.

What conditions does trial NCT04516694 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT04516694?

The interventions under investigation include: Financial incentive (gain) (BEHAVIORAL), Financial incentive (loss) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04516694?

This trial is sponsored by Harvard Pilgrim Health Care, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04516694 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.